Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | IDH2 | P48735 | 3/20 | 0.60 |
| ▸ | KIF11 | P52732 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | CTSC | P53634 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313912 | 1.00 | HDAC3 (0.67) | HDAC3HDAC1HDAC2HDAC6IDH2 | |
| SCHEMBL14378926 | 0.84 | IDH2 (0.63) | HDAC3HDAC1HDAC2HDAC6IDH2 | |
| SCHEMBL6663767 | 0.83 | AURKA (0.72) | HDAC3HDAC1HDAC2HDAC6IDH2 | |
| SCHEMBL31501743 | 0.83 | AURKA (0.72) | HDAC3HDAC1HDAC2HDAC6IDH2 | |
| SCHEMBL4140858 | 0.81 | CTSC (0.67) | HDAC3HDAC1HDAC2HDAC6IDH2 | |
| SCHEMBL4730181 | 0.80 | HDAC6 (1.00) | HDAC3HDAC1HDAC2HDAC6BTK | |
| SCHEMBL22452591 | 0.80 | KCNH2 (0.44) | HDAC3HDAC1HDAC2HDAC6AURKA | |
| SCHEMBL3600773 | 0.80 | HDAC3 (0.61) | HDAC3HDAC1HDAC2HDAC6IDH2 | |
| SCHEMBL3600005 | 0.80 | HDAC3 (0.61) | HDAC3HDAC1HDAC2HDAC6IDH2 | |
| SCHEMBL180866 | 0.79 | KDR (0.54) | AURKAKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | claimed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | claimed |
| EP-2010502-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2009-01-07 | — | — | EP | claimed |
| WO-2007125351-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2007-11-08 | — | — | WO | claimed |
| CN-111278818-B | BTK inhibitor compounds | 伊莱利利公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3707133-B1 | BTK INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| EP-3707133-A1 | BTK INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2020-09-16 | — | — | EP | disclosed |
| CN-111278818-A | BTK inhibitor compounds | 伊莱利利公司 | 2020-06-12 | — | — | CN | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-2010502-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007125351-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | HDAC3 4697/4885HDAC1 4706/4885HDAC2 4224/4885 |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | HDAC3 4697/4885HDAC1 4706/4885HDAC2 4224/4885 |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | BTK, SYK, LCK | HDAC3 1614/4885HDAC1 1748/4885HDAC2 833/4885 |
| US-11542249-B2 | BTK inhibitor compounds | BTK, SYK, LCK | HDAC3 1840/4885HDAC1 1715/4885HDAC2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.